Related references
Note: Only part of the references are listed.Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022
Benjamin N. Rome et al.
JAMA HEALTH FORUM (2023)
Out-of-pocket costs of biologic treatments for chronic rhinosinusitis with nasal polyposis in the Medicare population
Vinay K. Rathi et al.
INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY (2022)
Influence of omalizumab on treatment costs for chronic rhinosinusitis with nasal polyps and asthma: an insurance claims analysis
Lauren T. Roland et al.
INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY (2022)
Private payer-negotiated prices for FDA-approved biologic treatments for allergic diseases
Annette A. Wang et al.
INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY (2022)
Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps
George A. Scangas et al.
LARYNGOSCOPE (2021)
Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps
Anju T. Peters et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)
Omalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population
Pengxiang Li et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)
Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018
Inmaculada Hernandez et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials
Philippe Gevaert et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)